What is the main business of Poltiss?

The main business activity of Poltiss focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 10, 2015.

Where is the headquarters located?

The headquarters is located at: Al. Wojska Polskiego 150, 71-324 Szczecin.

Who is on the management board?

The management board consists of: Mirosława Helena El Fray (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 10,700 (approx. $2,890).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

The company reported a revenue of $3,844 in 2025, which is a decrease of 34.7% compared to 2024.

Is the company profitable?

No, in 2025 the company was not profitable, reporting a net loss of $8,996. For comparison, in 2024 the loss was $7,562, meaning the company increased its loss by 18.7%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $3,303 in 2025, representing 78% of all operating expenses.

Poltisssp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2015-09-10

Share capital

10 700,00 PLN

Activity description

Poltiss is a company that develops PhotoBioCure™ technology, which utilizes biopolymers that transform from a sticky liquid to flexible solids under UV radiation to create customized, biodegradable implants for tissue defects. Their biomaterials are designed for minimally invasive surgical procedures, eliminating the need for sutures and facilitating tissue regeneration. Founded in 2015, Poltiss focuses on improving the comfort of patients and surgeons through their programmable biopolymers.

Registered address

al. Wojska Polskiego 150/1, 71-324 Szczecin, Poland

Website

poltiss.com

Electronic delivery address

AE:PL-51307-78150-UTWDB-25

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 3.84kMedianUSD 38.31kAverageUSD 2.31m

Net profit

This companyUSD -9.00kMedianUSD -1.50kAverageUSD -84.98k

Operating costs

This companyUSD 4.23kMedianUSD 56.25kAverageUSD 2.29m

Assets

This companyUSD 9.12kMedianUSD 116.77kAverageUSD 2.72m

Industry

Bank accounts

Registered as a VAT taxpayer on 2019-03-01. Active

mBank
08 1140 2004 0000 3602 8076 0508
mBank
21 1140 2004 0000 3602 8076 0468
mBank
90 1140 2004 0000 3202 7567 5264

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

7 public aid cases recorded, with a total value of $646,802.

Grant date	Purpose	Gross amount	Granting body
Jul 20, 2023	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$2,142$2,142	Marszałek Województwa Zachodniopomorskiego
Apr 6, 2021	Aid for research and development projects: industrial research	$112.8K$112,779	Marszałek Województwa Zachodniopomorskiego
Apr 6, 2021	Aid for research and development projects: experimental development	$38,047$38,047	Marszałek Województwa Zachodniopomorskiego

European Funds

Start	Project	EU co-financing	Programme
2021-05-01	Opracowanie nowych funkcjonalności technologii PhotoBioCure oraz testy kliniczne w zakresie bezpieczeństwa i skuteczności.	$165.5K$165,533	Regionalny Program Operacyjny Województwa Zachodniopomorskiego 2014-2020

Tenders

No recorded participation in tenders.

Authorized Representatives

Mirosława El Fray — President of the Management Board

Manner of representation

If one person is appointed to the management board, the company shall be represented by one member of the management board independently; if more than one person is appointed to the management board, the company shall be represented by two members of the management board acting jointly or by a member of the management board jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
Bridge Alfa By Younick Mint Sp. z o.o. Sp. K.	54	$729.34	25.2336%
Mirosława Helena El Fray (61)	95	$1,283.09	44.3925%
Tomasz Jacek Łasecki (46)	51	$688.82	23.8318%
Others	14	$189.09	6.5421%

Beneficial owners

Person	Rights
Mirosława El Fray (61)	Shareholder of a limited liability company, 95.0 PLN
Tomasz Jacek Łasecki (46)	Shareholder of a limited liability company, 51.0 PLN
Jakub Żyto (57)	71% udziałów w younick mint spółce z o.o. w złotnikach będącej jedynym komplementariuszem wspólnika bridge alfa by younick mint spółka z ograniczoną odpowiedzialnością sp. k. w złotnikach

Competitors

Name	Revenue	Website
Stenocoatsp. z o.o.	$36,665.21	stenocoat.com
NanovelosS.A.	$24,842.03	nanovelos.com
2loop TechS.A.	$15,564.71	2loop.tech
Bio2materialssp. z o.o.	$14,121.59	bio2materials.com
Detoxedsp. z o.o.	$11,972.37	detoxed.pl
ArthecS.A.	$10,911.16	arthec.eu
Oncotherics PolandS.A.	$7,565.33	oncotherics.com
Fusiomicasp. z o.o.	$5,263.98	fusiomica.com
2loop Techsp. z o.o.	$3,513.01	2loop.tech
Passio Human Microbiomesp. z o.o.	$1,856.58	passiohumanmicrobiome.com

Change history

Date	Event
2023-12-20	Share capital change (10,600.00 PLN → 10,700.00 PLN)
2021-10-04	Address change (Al. Piastów 45/1/38, 71-311, Szczecin → Al. Wojska Polskiego 150/1, 71-324, Szczecin)
2021-06-29	Share capital change (10,060.00 PLN → 10,600.00 PLN)
2021-05-31	Share capital change (10,000.00 PLN → 10,060.00 PLN)
2018-07-30	Address change (Ul. Jagiellońska 20-21, 70-363, Szczecin → Al. Piastów 45/1/38, 71-311, Szczecin)

FAQ

Last updated: 2026-07-20